Sustained-release Ophthalmology Product


An injectable sustained-release ophthalmology product incorporating DURECT’s SABER® depot technology. The active pharmaceutical ingredient and indication have not been disclosed.

  • Reduced injection frequency
  • Reduced overall risk of injection-associated complications, such as injury and infection

This product is in pre-clinical development.

DURECT has licensed worldwide rights to develop and commercialize a sustained-release ophthalmology product utilizing DURECT’s SABER technology to Santen Pharmaceutical Co., Ltd. For a description of the associated terms, please see Collaborations.

Learn more about SABER technology

There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.